Civi­ca and Blue Cross Blue Shield launch new ven­ture to low­er gener­ic prices

Five years af­ter Mar­tin Shkre­li put a smug face to the volatile prices com­pa­nies can charge even for gener­ic drugs, pay­ers and gov­ern­ments are com­ing up with out­side-the-box so­lu­tions.

The lat­est fix is a new ven­ture from the Blue Cross Blue Shield As­so­ci­a­tion, 18 of its mem­bers and Civi­ca, the gener­ics com­pa­ny found­ed in 2018 by hos­pi­tals fed up with high prices for drugs that had long-since lost patent pro­tec­tion. While Civi­ca fo­cused on drugs that hos­pi­tals pur­chased, the new com­pa­ny will aim to low­er prices on drugs that, like Shkre­li’s Dara­prim, are pur­chased by in­di­vid­u­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER